Search results
BioGeneric Pharma S.A.E develops, produces, analyzes and markets recombinant proteins and vaccines, including mRNA technology. It has a state-of-the-art facility in the 10th of Ramadan Industrial City and a global network of partners.
BioGeneric Pharma S.A.E (BGP) is an international biopharmaceutical company whose principle activities are the development, production and marketing of therapeutic recombinant antibodies ,proteins and vaccines.
Announced on 21 June 2021, the objective of the technology transfer hub is to build capacity in low- and middle-income countries to produce mRNA vaccines through a centre of excellence and training (the mRNA vaccine technology hub).
BGP is a new state-of-the-art biopharmaceutical facility specialized in the manufacturing of: - Therapeutic recombinant proteins. - Preventive vaccines. Main activities. Research & Development (R&D) Production. Analysis. Marketing. mRNA Hub initiative by WHO. * mRNA vaccines have played an important role in the fight against the COVID-19 pandemic.
BGP is an international company that develops, produces, and markets biopharmaceutical products, including vaccines, biosimilars, and innovative drugs. It has a state-of-the-art facility in Cairo and collaborates with MPP and WHO to increase access to mRNA vaccines in the region.
BioGeneric Pharma S.A.E (BGP) is an international company that do development and production bio pharmaceuticals products.
Jan 28, 2023 · BioGeneric Pharma aims to achieve self-sufficiency in serums, vaccines, and biologics to reduce reliance on imported products and expand exports to African and international markets, the Cabinet said.
